SequelSEC

Milestone Pharmaceuticals Inc. MIST

Pharmaceutical Preparations · CIK 0001408443 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$559.00K
Fiscal year ended 2026-06-30
Operating income
-$25.63M
Fiscal year ended 2026-06-30
Free cash flow
-$22.74M
Fiscal year ended 2026-06-30

Milestone Pharmaceuticals Inc. (MIST) reported revenue of $559.00K and net income of -$28.61M for the fiscal year ended 2026-06-30. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Milestone Pharmaceuticals Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Milestone Pharmaceuticals Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Revenue$559.00K$238.00K$0$0
Cost of revenue$32.00K$14.00K$0$0
Gross profit$527.00K$224.00K$0$0
Operating income-$25.63M-$23.66M-$12.53M-$20.52M
Net income-$28.61M-$26.07M-$12.97M-$20.76M
Research & development$3.51M$3.25M$3.67M$4.98M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.21$-0.20$-0.20$-0.31
Selling, general & administrative$22.65MUnavailable$8.86MUnavailable
General & administrativeUnavailable$4.82M$3.76M$5.17M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Milestone Pharmaceuticals Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Cash & equivalents$169.73M$71.32M$42.50M$45.08M
Total assets$181.62M$193.73M$47.42M$61.88M
Current assets$180.33M$192.25M$46.17M$60.48M
Total liabilities$163.41M$157.68M$65.16M$68.01M
Current liabilities$22.18M$20.94M$9.28M$12.96M
Total equity incl. NCI$18.22M$36.05M-$17.74M-$6.12M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
Inventory$4.72M$1.83MUnavailableUnavailable
Accounts receivable$2.72M$1.60MUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debt$59.21M$58.19M$55.24M$54.29M
Accounts payable$8.45M$10.02MUnavailableUnavailable

Cash flow

Milestone Pharmaceuticals Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Operating cash flow-$22.71M-$16.05M-$12.57M-$13.95M
Capital expenditures$26.00K$45.00K$11.00K$6.00K
Investing cash flow$111.99M-$80.03M$9.94M$33.58M
Financing cash flow$9.13M$94.35M$36.00K$140.00K
Net change in cash$98.41M-$1.73M-$2.59M$19.77M
Stock-based compensation$1.34M$1.28M$1.31M$1.35M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$57.00K$56.00K$28.00K$27.00K

Derived

Milestone Pharmaceuticals Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Free cash flow-$22.74M-$16.10M-$12.58M-$13.96M
Gross margin94.3%94.1%UnavailableUnavailable
Operating margin-4585.0%-9942.4%UnavailableUnavailable
FCF margin-4068.0%-6763.9%UnavailableUnavailable
SBC / revenue239.4%538.7%UnavailableUnavailable
Current ratio8.13x9.18x4.97x4.67x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net margin-5118.8%-10952.1%UnavailableUnavailable
R&D / revenue627.7%1366.0%UnavailableUnavailable
CapEx / revenue4.7%18.9%UnavailableUnavailable
Long-term debt / equity3.25xUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MIST in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-20View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.